Only the Oncotype DX test can identify patients who will and will not benefit from chemotherapy.1-5 EndoPredict® cannot.
The Oncotype DX Breast Recurrence Score test predicts both chemotherapy benefit and lack of benefit.1,2
EndoPredict lacks clinical evidence showing that patients with EPclin high-risk results will benefit from chemotherapy
||Breast Recurrence Score test
|Evidence showing a statistically significant interaction between the test and treatment outcomes?
|Randomized, clinical trial data published?
|Validation studies in pre- and post-menopausal, node-negative patients?
|Meets highest level of evidence in recognized guidelines for treating invasive breast cancer?
EndoPredict® may lead to unnecessary chemotherapy treatment based on its risk classification result
Many patients are categorized as EPclin high risk based on the EPclin algorithm*, which is strongly influenced by clinicopathologic features10
EndoPredict still has not been validated to show prediction of
- EndoPredict claims to be chemopredictive, but lacks randomized data within a homogenized cohort
- EndoPredict does not stratify patients by nodal status, significantly skewing recurrence risks
- Effect of chemotherapy does not vary between EPclin and EP molecular score results, suggesting that EndoPredict does not add any additional information beyond clinicopathologic features
Only the Oncotype DX Breast Recurrence Score® test has been proven to predict chemotherapy benefit in both node-negative and node-positive patients2,4